Type 2 Diabetes Therapy

Simvastatin lowers factors associated with heart attack in type 2 diabetic patients

Published in Obesity and Diabetes Week, February 3rd, 2003

by Maria G. Essig, MS, ELS, senior medical writer - Type 2 diabetic patients who received the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor simvastatin experienced significant decreases in levels of high-sensitivity C-reactive protein (hs-CRP) and low-density lipoprotein (LDL) cholesterol, according to a report in the Journal of Diabetes and its Complications.

"High-sensitivity C-reactive protein is positively associated with the prevalence of coronary artery disease by epidemiologic data," said I-Te Lee and colleagues at Taichung Veterans General Hospital in Taiwan. "Type 2 diabetes is associated with high mortality risk of coronary heart...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry